NBIX Overview

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.

Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is179.68 USD with a low forecast of 143.00 USD and a high forecast of 203.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Neurocrine Biosciences, Inc revenue for the last quarter amounts to 814.50M USD, increased 42.25

Neurocrine Biosciences, Inc. EPS for the last quarter amounts to 1.91 USD, increased 2287.50

Neurocrine Biosciences, Inc (NBIX) has 2000 emplpoyees as of May 31 2026.

Today NBIX has the market capitalization of 15.92B USD.